ViewRay, Inc. (6L9.F) Surges 2400% on Extreme Intraday Volatility

ViewRay, Inc. (6L9.F) experienced an extraordinary 2400% intraday surge on the XETRA exchange, climbing to €0.025 from an opening price of €0.001. The medical device manufacturer, which designs MRI-guided radiation therapy systems, saw trading volume spike to 3,500 shares, roughly 12.5 times its average daily volume. However, this dramatic price movement masks severe underlying challenges: the company reported a negative EPS of -0.55 and continues burning cash. The stock trades far below its 50-day average of €0.31916 and 200-day average of €2.71739, reflecting a year-long collapse.

Extreme Volatility Masks Fundamental Weakness

The 2400% jump represents a classic penny-stock bounce from near-zero levels rather than genuine business recovery. ViewRay opened at €0.001, the lowest point in its trading range, before climbing to the day’s high of €0.025. This type of extreme move occurs when minimal trading volume creates outsized percentage swings. The company’s market cap stands at approximately €207.2 million, yet profitability remains elusive. Operating margins are deeply negative at -104.8%, meaning the company loses more than one euro for every euro of revenue generated. The stock trades at a price-to-book ratio of just 0.064, suggesting the market values the company far below its tangible assets, a red flag for distressed businesses.

Cash Burn and Negative Cash Flow Threaten Viability

ViewRay’s financial metrics reveal a company in distress. Free cash flow per share stands at -€0.529, indicating the company burns cash from operations. Operating cash flow is similarly negative at -€0.508 per share, while the company maintains only €0.752 in cash per share. The debt-to-equity ratio of 1.05 shows the company carries substantial leverage relative to shareholder equity. With negative net income per share of -€0.594, ViewRay loses money on every unit sold. The company’s current ratio of 2.36 provides some liquidity cushion, but this masks the underlying cash burn problem. Track 6L9.F on Meyka for real-time updates on this volatile medical device stock.

MRIdian Technology Faces Market Adoption Headwinds

ViewRay’s core product, the MRIdian system, combines MRI imaging with radiation therapy to treat cancer patients. The technology addresses real clinical needs: reducing beam distortion, minimizing skin toxicity, and improving treatment precision. However, adoption has lagged expectations. The company serves university hospitals, community facilities, and cancer centers across the US, France, Taiwan, and the UK. With 2,950 full-time employees and headquarters in Oakwood, Ohio, ViewRay maintains significant fixed costs. Revenue per share of only €0.566 fails to cover operating expenses, resulting in the massive operating losses. The price-to-sales ratio of 2.36 appears reasonable on the surface, but reflects a market skeptical of near-term profitability.

Meyka AI Grade and Sector Context

Meyka AI rates 6L9.F with a grade of C+, suggesting a HOLD recommendation with a total score of 57.86 out of 100. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Within the Healthcare sector on XETRA, ViewRay underperforms peers. The sector averages a PE ratio of 28.71 and ROE of 16.0%, while ViewRay’s negative earnings and -85.2% ROE place it among the weakest performers. The company’s year-to-date decline of -99.4% and five-year loss of -99.7% reflect a long-term value destruction story that today’s volatility cannot reverse.

Final Thoughts

ViewRay’s 2400% intraday surge represents extreme volatility driven by minimal trading volume rather than fundamental improvement. The medical device maker faces severe profitability challenges, negative cash flow, and mounting losses that threaten long-term viability. While the MRIdian technology addresses real clinical needs, market adoption remains insufficient to cover operating costs. Meyka AI’s C+ grade reflects these headwinds. Investors should recognize this spike as a technical bounce in a deeply distressed stock, not a reversal signal. The company requires significant operational turnaround and market traction to justify current valuations.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.